GET DAILY SIGNALSFESM vs SCHA: Active Factor Strategies Against Low-Cost Small-Cap Indexing
Key Takeaways
- FESM is an actively managed, semi-transparent small-cap strategy that starts from the Russell 2000 universe and applies computer-aided, factor-driven stock selection, while SCHA is a passive index fund tracking the Dow Jones U.S. Small-Cap Total Stock Market Index.
- Cost structure is a key differentiator: SCHA charges just 0.04%, among the lowest in the small-cap category, versus FESM's 0.28% net expense ratio.
- Diversification profile favors SCHA, which holds roughly 1,750 names, compared with FESM's approximately 900 positions.
- Relative positioning differs in concentration: FESM's top holdings carry meaningfully larger individual weights, reflecting active conviction, while SCHA's top ten names account for only about 3% of assets.
- Historical performance has favored FESM, which has repeatedly ranked in the top quintile of its category across one-, three-, five-, and ten-year periods.
- Tickeron AI Verdict: FESM is the favored ticker for investors prioritizing factor-driven active management and a track record of category outperformance.
Why Compare These Two Small-Cap ETFs
Both FESM and SCHA target U.S. small-capitalization equities, yet they represent two distinct approaches to the same investor goal: capturing the long-term growth potential of smaller companies. FESM is an actively managed, semi-transparent fund that seeks to outperform its benchmark through systematic factor analysis, while SCHA is a broad, ultra-low-cost index fund designed simply to replicate the small-cap segment of the total U.S. stock market. Because small caps are especially sensitive to interest rates, credit conditions, and domestic economic momentum, comparing these two funds offers a timely ETF comparison of cost, diversification, and relative positioning within a high-conviction versus broad-market framework.
Understanding FESM's Active Approach
FESM, launched in December 2007 by Fidelity, is an actively managed fund that normally invests at least 80% of its assets in stocks from the Russell 2000 Index. Its advisor applies a research-driven, computer-aided approach focused on long-term drivers of returns such as valuation, growth, quality, and other factors. The fund holds approximately 900 securities and carries a net expense ratio of 0.28%, with assets under management (AUM) of roughly $6.4 billion. Sector exposure is led by healthcare (about 21%), technology (about 18%), financials (about 17%), and industrials (about 14%). Representative top holdings include GKOS (Glaukos), CMC (Commercial Metals), FLR (Fluor), IBP (Installed Building Products), and OSCR (Oscar Health). As a semi-transparent active fund, FESM discloses holdings less frequently than fully transparent index ETFs, and its portfolio turnover is higher, reflecting ongoing tactical adjustments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
SCHA's Passive, Low-Cost Strategy
SCHA, launched in November 2009 by Charles Schwab, is a passively managed fund that seeks to track the Dow Jones U.S. Small-Cap Total Stock Market Index, which covers the small-cap portion (components ranked 751–2500 by full market capitalization) of the broader U.S. market. The fund holds approximately 1,750 stocks and charges an expense ratio of just 0.04%, with AUM exceeding $22 billion, making it one of the largest and most liquid small-cap ETFs. Sector allocation is led by financials, healthcare, technology, and industrials, each in the mid-teens percentage range. Its top holdings are small individual weights, including HALO (Halozyme Therapeutics), TWST (Twist Bioscience), SANM (Sanmina), W (Wayfair), and HL (Hecla Mining). With a float-adjusted, market-cap-weighted methodology and low turnover, SCHA provides broad, inexpensive, and highly diversified small-cap exposure.
The Current Small-Cap Environment
The U.S. small-cap segment remains a focal point for investors assessing the direction of Federal Reserve policy, credit availability, and domestic growth. Smaller companies typically carry more floating-rate debt and generate a larger share of revenue domestically, making them particularly responsive to interest-rate expectations and regional economic strength. Recent market cycles have seen periodic rotation into small caps as investors weigh valuation gaps between large-cap growth leaders and smaller, cheaper equities. Within the small-cap universe, healthcare and technology innovation, regional banking resilience, and industrial re-shoring trends have been notable catalysts. Key risks include sensitivity to tightening financial conditions, earnings volatility among smaller firms, and elevated beta relative to large-cap benchmarks. These dynamics shape the environment in which both FESM and SCHA operate.
Performance and Positioning Insights
Over recent market cycles, FESM has delivered notably strong relative results, repeatedly ranking in the top quintile of the small-cap blend category and outpacing the Russell 2000 on a one-, five-, and ten-year basis. This reflects its factor-based tilt toward quality and growth characteristics. SCHA, by contrast, has tracked the broader small-cap market closely, offering predictable index-like returns with minimal tracking error. The two funds also differ in volatility and positioning: FESM's concentrated active bets and healthcare and technology overweights introduce greater active risk, while SCHA's vast breadth and sector-neutral approach dampen single-stock risk. Both carry a beta above one, signaling greater price swings than the S&P 500. For cost-conscious, index-oriented investors, SCHA's 0.04% fee is compelling; for those seeking a performance-seeking factor strategy, FESM's historical edge has been substantial.
Integrating AI Tools Into ETF Analysis
In my own research process, I regularly use Tickeron’s AI Screener to quickly compare ETFs like these on factors such as expense ratios, holdings overlap, sector tilts, and historical risk-adjusted returns. It helps surface how an active fund’s factor tilts stack up against a passive benchmark without spending hours on manual data pulls. The tool’s customizable filters for performance, volatility, and AI-driven signals have become a standard part of evaluating whether the active edge in a fund like FESM justifies its higher cost relative to something as efficient as SCHA.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
SCHA in upward trend: 10-day moving average moved above 50-day moving average on November 13, 2026
The 10-day moving average for SCHA crossed bullishly above the 50-day moving average on November 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SCHA's RSI Indicator exited the oversold zone, 20 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for SCHA just turned positive on October 21, 2026. Looking at past instances where SCHA's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCHA advanced for three days, in 269 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 228 of 270 cases where SCHA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 65 cases where SCHA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SCHA as a result. In 80 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
SCHA moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
SCHA broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Advertisement